基于新灰色关联法分析某医院冠心病患者DRG超支病例用药情况  

Analysis of the Medication in DRG Overspending Cases of Coronary Heart Disease Patients Based on a New Grey Correlation Method

作　　者：夏蕾 哈维超 李梦媛[2] 郜苏苏 XIA Lei;HA Weichao;LI Mengyuan;GAO Susu(School of Pharmacy,Nanjing Medial University,Nanjing 210000,China;Department of Pharmacy,the Second Affiliated Hospital of Nanjing Medical University,Nanjing 210011,China)

机构地区：[1]南京医科大学药学院,南京210000 [2]南京医科大学第二附属医院药学部,南京210011

出　　处：《药学与临床研究》2024年第4期371-375,共5页Pharmaceutical and Clinical Research

基　　金：江苏省老年医学学会2023年度临床药学专项基金科研项目(JGS2023MSYX015)。

摘　　要：目的:探究按疾病诊断相关分组(DRG)付费方式政策实施后,冠心病住院患者药品费用超支情况及各因素之间的关联性。方法:收集2022年1月-2023年3月南京医科大学第二附属医院冠心病住院患者基本费用信息和用药情况,应用新灰色关联法分析总药品费用与各类药品金额之间的关联性。结果:共纳入病例数为1421例,超支病例占总病例数的47.15%,其中有53.73%的病例超支主要原因为西药。药品费用关联度前三位的药品分类分别是消化道和代谢方面药物、心血管系统药物、血液和造血器官药物;依诺肝素和辅助用药烟酰胺、丹参酮ⅡA磺酸钠注射液的费用是影响住院患者总药品费用的主要因素。结论:DRG政策下冠心病住院患者的药品费用虽得到一定的合理管控,但辅助用药的使用仍需重点监控。Objective:To explore the drug cost overrun of hospitalized patients with coronary heart disease and the correlation between various factors after the implementation of the Diagnosis Related Groups(DRG)payment policy.Methods:Basic cost and medication information of inpatients with coronary heart disease from January 2022 to March 2023 in the Second Affiliated Hospital of Nanjing Medical University were collected,a new grey correlation method was used to analyze the correlation between the total drug cost and the amount of various drugs.Results:A total of 1421 cases were included,and the overspend cases accounted for 47.15%of the total cases,of which 53.73%of the cases were mainly due to Western medicine.The top three correlations of the total drug cost of hospitalized patients with coronary heart disease were the cost of drugs in the digestive tracts and metabolism,cardiovascular system drugs,and blood and hematopoietic organ drugs,the cost of enoxaparin sodium and adjuvant drugs such as nicotinamide and sulfotanshinone sodium injections were the main factors affecting the total drug cost of inpatients.Conclusion:Although the drug costs for hospitalized patients with coronary heart disease under the DRG policy have been reasonably controlled,the use of adjuvant drugs still needs to be closely monitored.

关 键 词：DRG付费 新灰色关联法 冠心病 药品费用 

分 类 号：R95[医药卫生—药学]